IPAMORELIN

Overview

Ipamorelin is under investigation for its potential to stimulate the secretion of growth hormone (GH) without significantly affecting other hormones such as cortisol or prolactin. Its mechanism involves selective activation of the ghrelin receptor, leading to GH release.

Product Research

• Growth Hormone Secretion

  Ipamorelin has been shown to effectively stimulate GH release both in vitro and in vivo. Studies demonstrate that it induces GH secretion in a dose-dependent manner without significantly altering levels of other pituitary hormones. [1]

• Bone Growth

  Research indicates that ipamorelin can promote longitudinal bone growth. In animal studies, administration of ipamorelin resulted in increased bone growth rates, suggesting its potential utility in bone development research. [2]

• Insulin Secretion

  Investigations into the effects of ipamorelin on pancreatic function have shown that it can evoke insulin release. This effect is mediated through calcium channel and adrenergic receptor pathways, highlighting a potential area for metabolic research. [3]

• Pharmacokinetics in Humans

  Clinical trials involving healthy volunteers have examined the pharmacokinetics and pharmacodynamics of ipamorelin. The peptide exhibits a short half-life and dose-proportional pharmacokinetics, with a rapid onset of GH release following administration. [4]

• Body Composition Effects

  Studies in animal models have explored the impact of ipamorelin on body composition. Results suggest that chronic administration leads to increased body weight gain, primarily through lean mass accumulation, without significant effects on fat mass. [5]

Disclaimer

This product is intended for laboratory research and development purposes only. It is not approved for human consumption, medical, or veterinary use. All information provided is for scientific reference only. Use under the supervision of qualified professionals in appropriate research settings.

Referenced Citations

1. Ipamorelin, the first selective growth hormone secretagogue – PubMed
2. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats – PubMed
3. Mechanism of ipamorelin-evoked insulin release from the pancreas – PubMed
4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers – PubMed
5. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats – PubMed